EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Uncovering barriers to early diagnosis of Alzheimer's disease: a European perspective

David A. Pérez‐Martínez, Anne‐Charlotte Jarry, Gabriel Martino, Giancarlo Pesce, Izabela Pieniazek, Jenny Presto, Patryk Miernik, Roman Casciano, Kristian Steen Frederiksen

Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2025-10 · 11 (4)

DOI: 10.1002/trc2.70178 ↗
AbstractBibliografische Angaben

Abstract

Abstract INTRODUCTION Timely and accurate diagnosis of early Alzheimer's disease (AD) is critical to maximizing the potential benefits of disease‐modifying therapies; however, it remains a challenge in clinical practice. METHODS A double‐blind survey was conducted among general practitioners (GPs; n = 52) and AD specialists (neurologists, psychiatrists, geriatricians, and others; n = 75) across five European countries to evaluate healthcare practitioners’ (HCPs) perceptions of diagnosing AD. Data from all countries were pooled and presented overall. RESULTS GPs are usually the first point of contact for patients with mild cognitive impairment (MCI)/AD. Only 30% of patients received a formal diagnosis of AD during the MCI stage, and it took patients 15.2 months from symptom onset to their first primary care visit. The most common challenges identified by HCPs were referral times, lack of effective treatment, and resource and time constraints. DISCUSSION Systemic reforms are required to remove barriers in early AD diagnosis, including tailored training and coordinated care between GPs and AD specialists. Highlights Timely diagnosis of eAD remains a major challenge in clinical practice. Only one‐third of patients received a formal diagnosis of AD during the MCI stage. It took patients 15.2 months from symptom onset to first primary care visit. Key diagnostic barriers include referral delays and lack of effective treatments. Addressing these issues may improve eAD diagnosis and timely intervention.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →